Number of studies | OR or HR (95% CI) | Heterogeneity | Favor | |
---|---|---|---|---|
Randomized controlled trial | ||||
CR | 2 | 0.11 (0.03, 0.43), P = 0.001 | I2 = 0% | Combined |
TR | 2 | 0.50 (0.21, 1.21), P = 0.13 | I2 = 0% | – |
DC | 2 | 0.38 (0.11, 1.36), P = 0.14 | I2 = 0% | – |
PFS | 2 | 1.80 (1.29, 2.50), P = 0.0005 | I2 = 0% | Combined |
Retrospective | ||||
CR | 4 | 0.26 (0.15, 0.47), P < 0.00001 | I2 = 27% | Combined |
TR | 4 | 0.24 (0.10, 0.58), P = 0.001 | I2 = 78% | Combined |
DC | 4 | 0.18 (0.09, 0.36), P < 0.0001 | I2 = 9% | Combined |
Myelosuppression | 3 | 0.62 (0.39, 1.00), P = 0.05 | I2 = 0% | – |
Gastrointestinal response | 3 | 0.86 (0.55, 1.35), P = 0.52 | I2 = 0% | – |
PFS | 4 | 1.45 (1.10, 1.90), P = 0.009 | I2 = 67% | Combined |
OS | 4 | 1.40 (1.22, 1.60), P < 0.0001 | I2 = 0% | Combined |